Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 7/20 | 0.64 |
| ▸ | PGR | P06401 | 1/20 | 0.64 |
| ▸ | GLUL | P15104 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12917991 | 0.95 | NR3C1 (0.59) | NR3C1PGRGLUL | |
| SCHEMBL13581527 | 0.87 | NR3C1 (0.65) | NR3C1PGRGLUL | |
| SCHEMBL12956264 | 0.87 | NR3C1 (0.69) | NR3C1PGRGLUL | |
| SCHEMBL12956411 | 0.87 | NR3C1 (0.67) | NR3C1PGRGLUL | |
| SCHEMBL16312972 | 0.86 | NR3C1 (0.61) | NR3C1PGRGLUL | |
| SCHEMBL12956258 | 0.84 | NR3C1 (0.68) | NR3C1PGRGLUL | |
| SCHEMBL12956172 | 0.84 | NR3C1 (0.67) | NR3C1PGRGLUL | |
| SCHEMBL12956574 | 0.83 | NR3C1 (0.65) | NR3C1PGRGLUL | |
| SCHEMBL12918239 | 0.82 | NR3C1 (0.60) | NR3C1PGRGLUL | |
| SCHEMBL12947476 | 0.81 | NR3C1 (0.66) | NR3C1PGRGLUL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625937-B2 | 1H-benzo[F]indazol-5-YL derivatives as selective glucocorticoid receptor modulators | MERCK & CO., INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625937-B2 | 1H-benzo[F]indazol-5-YL derivatives as selective glucocorticoid receptor modulators | MERCK & CO., INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20080076795-A1 | 1H-benzo[F]indazol-5-YL derivatives as selective glucocorticoid receptor modulators | MERCK SHARP & DOHME CORP. | 2008-03-27 | — | — | US | disclosed |
| US-20080076795-A1 | 1H-benzo[F]indazol-5-YL derivatives as selective glucocorticoid receptor modulators | MERCK SHARP & DOHME CORP. | 2008-03-27 | — | — | US | disclosed |
| US-7282591-B2 | 1h-benzo{f}indazol-5-yl derivatives as selective glucocorticoid receptor modulators | MERCK & CO., INC. (US) | 2007-10-16 | — | — | US | disclosed |
| US-7282591-B2 | 1h-benzo{f}indazol-5-yl derivatives as selective glucocorticoid receptor modulators | MERCK & CO., INC. (US) | 2007-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076795-A1 | 1H-benzo[F]indazol-5-YL derivatives as selective glucocorticoid receptor modulators | NR3C1, NR3C2, GRK5 | NR3C1 1/4885PGR 135/4885GLUL 2420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.